11 high-impact drugs to look out for in 2026 Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

#obesity #type2diabetes #rarediseases #cancer #oncology #womenshealth #NovoNordisk #EliLilly #Lilly #GSK #severeasthma #JnJ #biologics #Otsuka #IgAN #kidneydisease #Sanofi #MS #BeOneMedicines #CLL #SLL #BMS #CELMoD #multiplemyeloma #Pfizer #breastcancer #CorceptTherapeutics #SGRA
zurl.co/xauLJ

How can pharmacists best support patients with chronic lymphocytic leukaemia? Over the past decade, the development of targeted therapies has significantly changed the way that chronic lymphocytic leukaemia (CLL) is treated. Survival and life expectancy has improved, and this…

*How can pharmacists best support patients with chronic lymphocytic leukaemia?*

As therapies for #CLL have evolved, so has pharmacists’ role in treating people with this type of blood cancer

Supported by #BeOneMedicines

Supporting pharmacists in improving the care delivered for people with cancer Pharmacists are playing an increasingly important role in supporting people with cancer, working within multidisciplinary teams and improving outcomes. Around 3.5 million people are currently living…

*Supporting pharmacists in improving the care delivered for people with cancer*

#ThePJ's cancer ‘hub page’ includes educational resources on blood cancer as part of continued partnership with #BeOneMedicines

How can pharmacists best support patients with chronic lymphocytic leukaemia? Over the past decade, the development of targeted therapies has significantly changed the way that chronic lymphocytic leukaemia (CLL) is treated. Survival and life expectancy has improved, and this…

*How can pharmacists best support patients with chronic lymphocytic leukaemia?*

As therapies for #CLL have evolved, so has pharmacists’ role in treating people with this type of blood cancer

Supported by #BeOneMedicines

Management of Waldenstrom's macroglobulinaemia Introduction Waldenstrom’s macroglobulinaemia (WM) is a rare type of non-hodgkin lymphoma, characterised by the presence of a monoclonal IgM protein​[1,2]​. Approximately 350 people are diagnosed…

*Management of Waldenstrom’s macroglobulinaemia*

An overview of the symptoms and diagnosis of Waldenstrom’s macroglobulinaemia, as well as treatment options

Supported by #BeOneMedicines

Chronic lymphocytic leukaemia: diagnosis and management Introduction Chronic lymphocytic leukaemia (CLL) is a form of blood cancer affecting the lymphocytes. The term ‘chronic’ derives from the fact that this type of leukaemia is slow growing, compared to…

*Chronic lymphocytic leukaemia: diagnosis and management*

An overview of how to diagnose, manage and monitor patients with CLL, emphasising the important role of pharmacists

Supported by #BeOneMedicines

Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…

*BTK inhibitors and B-cell malignancies: a guide for pharmacists*

This article provides an overview of the available BTK inhibitors for the treatment of B-cell malignancies to support pharmacists with their use in practice. Supported by #BeOneMedicines

Supporting pharmacists in improving the care delivered for people with cancer Pharmacists are playing an increasingly important role in supporting people with cancer, working within multidisciplinary teams and improving outcomes. Around 3.5 million people are currently living…

*Supporting pharmacists in improving the care delivered for people with cancer*

#ThePJ's cancer ‘hub page’ includes educational resources on blood cancer as part of continued partnership with #BeOneMedicines

How can pharmacists best support patients with chronic lymphocytic leukaemia? Over the past decade, the development of targeted therapies has significantly changed the way that chronic lymphocytic leukaemia (CLL) is treated. Survival and life expectancy has improved, and this…

*How can pharmacists best support patients with chronic lymphocytic leukaemia?*

As therapies for #CLL have evolved, so has pharmacists’ role in treating people with this type of blood cancer

Supported by #BeOneMedicines

Management of Waldenstrom's macroglobulinaemia Introduction Waldenstrom’s macroglobulinaemia (WM) is a rare type of non-hodgkin lymphoma, characterised by the presence of a monoclonal IgM protein​[1,2]​. Approximately 350 people are diagnosed…

*Management of Waldenstrom’s macroglobulinaemia*

An overview of the symptoms and diagnosis of Waldenstrom’s macroglobulinaemia, as well as treatment options

Supported by #BeOneMedicines

Chronic lymphocytic leukaemia: diagnosis and management Introduction Chronic lymphocytic leukaemia (CLL) is a form of blood cancer affecting the lymphocytes. The term ‘chronic’ derives from the fact that this type of leukaemia is slow growing, compared to…

*Chronic lymphocytic leukaemia: diagnosis and management*

An overview of how to diagnose, manage and monitor patients with CLL, emphasising the important role of pharmacists

Supported by #BeOneMedicines

Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…

*Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists*

This learning article provides an overview of the available BTK inhibitors for the treatment of B-cell malignancies to support pharmacists with their use in practice. Supported by #BeOneMedicines

Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…

This interactive learning article, supported by #BeOneMedicines, provides an overview of the available #BTKIs for the treatment of B-cell malignancies to support pharmacists with their use in practice

#cancercare #cancertreatment #pharmacy

Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…

This interactive learning article, supported by #BeOneMedicines, provides an overview of the available #BTKIs for the treatment of B-cell malignancies to support pharmacists with their use in practice

#cancercare #cancertreatment #pharmacy

Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…

This interactive learning article, supported by #BeOneMedicines, provides an overview of the available Bruton tyrosine kinase inhibitors for the treatment of B-cell malignancies to support pharmacists with their use in practice

#BTKIs #cancercare #cancertreatment #pharmacy

Cancer As the number of patients being diagnosed and living with cancer continues to grow, pharmacists are playing an increasingly important role in supporting patients, working within multidisciplinary…

This new collection of cancer content, brought to you in partnership with BeOne Medicines, provides access to educational resources that support professional development for improved patient

#cancercare #BeOneMedicines #cancermedication

Investition in das Morgen: Gesundheit durch neue Krebs-Medikamente Dr. Xiaobin Wu vom Onkologieunternehmen BeOne Medicines über den Einsatz gegen Krebs und das Ziel, die Forschung effizienter zu gestalten.

Dr. Xiaobin Wu vom Onkologieunternehmen #BeOneMedicines über den Einsatz gegen #Krebs und das Ziel, die #Forschung effizienter zu gestalten: pharma-fakten.de/news/investi...

Ich möchte ja so gerne wissen, was für ein sensationelles Angebot die Stadt #Basel #BeOneMedicines für ihren Hauptsitz gemacht hat, dass es vorteilhafter ist als auf den #CaymanIsland. Frage für die SP und für die @woz.ch?